Study Data from Icahn School of Medicine at Mount Sinai Update Knowledge of Bladder Cancer (Induction and Maintenance of Sequential Intravesical Gemcitabine/docetaxel for Intermediate and High-risk Non-muscle Invasive Bladder Cancer With...).

A study conducted by researchers at the Icahn School of Medicine at Mount Sinai in New York City examined the efficacy of sequential intravesical gemcitabine and docetaxel (Gem/Doce) chemotherapy for non-muscle invasive bladder cancer (NMIBC). The study compared the outcomes of Gem/Doce induction alone versus induction with maintenance, as well as different dosage protocols. The analysis included 83 patients with a median age of 73, and the results showed that Gem/Doce induction with maintenance resulted in significantly better recurrence-free survival (RFS) compared to induction-only. However, further prospective trials are needed to validate these findings. [Extracted from the article]